[go: up one dir, main page]

NO20062193L - Bisykliske [3.1.0] derivater som glysintransportorinhibitorer - Google Patents

Bisykliske [3.1.0] derivater som glysintransportorinhibitorer

Info

Publication number
NO20062193L
NO20062193L NO20062193A NO20062193A NO20062193L NO 20062193 L NO20062193 L NO 20062193L NO 20062193 A NO20062193 A NO 20062193A NO 20062193 A NO20062193 A NO 20062193A NO 20062193 L NO20062193 L NO 20062193L
Authority
NO
Norway
Prior art keywords
bicyclic
derivatives
transporter inhibitors
glycine transporter
psychoses
Prior art date
Application number
NO20062193A
Other languages
English (en)
Other versions
NO337361B1 (no
Inventor
John Lowe
Stan Mchardy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34465157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062193(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO20062193L publication Critical patent/NO20062193L/no
Publication of NO337361B1 publication Critical patent/NO337361B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en serie av substituerte bicykliske [3.1.0]aminer med formel I: hvori A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30. o, p, s, t og q er som definert i beskrivelsen, deres farmasøytisk akseptable salter, farmasøytiske sammensetninger derav og deres anvendelse for å forbedre kognisjon og behandling av positive og negative symptomer på schizofreni og andre psykoser hos pattedyr, som inkluderer mennesker.
NO20062193A 2003-10-14 2006-05-15 Bicykliske[3.1.0] derivater som glysintransportørinhibitorer, og farmasøytiske sammensetninger inneholdende slike. NO337361B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51084603P 2003-10-14 2003-10-14
PCT/US2004/034083 WO2005037216A2 (en) 2003-10-14 2004-10-14 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors

Publications (2)

Publication Number Publication Date
NO20062193L true NO20062193L (no) 2006-05-15
NO337361B1 NO337361B1 (no) 2016-03-29

Family

ID=34465157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062193A NO337361B1 (no) 2003-10-14 2006-05-15 Bicykliske[3.1.0] derivater som glysintransportørinhibitorer, og farmasøytiske sammensetninger inneholdende slike.

Country Status (26)

Country Link
US (1) US7473787B2 (no)
EP (1) EP1680124B1 (no)
JP (2) JP4732354B2 (no)
KR (1) KR20060095865A (no)
CN (2) CN101838271A (no)
AP (1) AP2006003592A0 (no)
AU (1) AU2004281794B2 (no)
BR (1) BRPI0415356A (no)
CA (1) CA2542279C (no)
CR (2) CR8333A (no)
DK (1) DK1680124T3 (no)
EA (1) EA009903B1 (no)
EC (1) ECSP066504A (no)
ES (1) ES2634841T3 (no)
GE (1) GEP20104959B (no)
IL (1) IL174299A (no)
IS (1) IS8355A (no)
MA (1) MA28094A1 (no)
MX (1) MXPA06004279A (no)
NO (1) NO337361B1 (no)
NZ (1) NZ546012A (no)
RS (1) RS20060190A (no)
TN (1) TNSN06109A1 (no)
UA (1) UA86037C2 (no)
WO (1) WO2005037216A2 (no)
ZA (1) ZA200602174B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339422B1 (no) * 2005-04-08 2016-12-12 Pfizer Prod Inc Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
WO2006002133A1 (en) * 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
US8470849B2 (en) * 2007-11-05 2013-06-25 Merck Patent Gmbh 7-azaindole derivatives as selective 11-β-hydroxysteroid dehydrogenase type 1 inhibitors
WO2010068851A1 (en) * 2008-12-12 2010-06-17 Vanderbilt Universtiy 3.3.0 bicyclic glyt1 inhibitors and methods of making and using same
RU2011124709A (ru) * 2008-12-29 2013-02-10 Вандербилт Юниверсити ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
FR2944283B1 (fr) * 2009-04-14 2011-05-06 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
JPWO2010107115A1 (ja) * 2009-03-19 2012-09-20 大正製薬株式会社 グリシントランスポーター阻害物質
WO2012036278A1 (ja) 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN103319645B (zh) * 2013-05-31 2016-08-10 南京洁雅新材料有限公司 一种水性金属保护剂及其生产工艺
JP6581111B2 (ja) * 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
KR20180052678A (ko) 2015-09-16 2018-05-18 메타크린, 인크. 파네소이드 x 수용체 아고니스트 및 이의 용도
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP2018532772A (ja) 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
AU2020266566B2 (en) * 2019-05-01 2025-11-06 Boehringer Ingelheim International Gmbh Solid forms of a GlyT1 inhibitor
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A2 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US12059408B2 (en) 2020-08-13 2024-08-13 Boehringer Ingelheim International Gmbh Treatment of cognitive impairment associated with schizophrenia
WO2022078927A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4
CN119039274A (zh) * 2023-05-29 2024-11-29 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK113998A3 (en) * 1996-03-29 2001-05-10 Pfizer 6-phenylpyridyl-2-amine derivatives
CN1327383A (zh) * 1996-05-31 2001-12-19 阿列里克斯神经科学公司 治疗神经和神经精神障碍的药物
US6897230B2 (en) * 2001-04-17 2005-05-24 Kyorin Pharmaceutical Co., Ltd. Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof
CA2463264C (en) * 2001-10-22 2009-05-26 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
EP1442018A1 (en) 2001-10-31 2004-08-04 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Novel anticancer compounds
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
EP1546099B1 (en) * 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
DE60231341D1 (de) * 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
WO2004089900A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
KR20060096038A (ko) * 2003-10-16 2006-09-05 화이자 프로덕츠 인크. 3-아자비시클로〔3.1.0〕헥산 유도체의 제조법
DK2447252T3 (da) 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339422B1 (no) * 2005-04-08 2016-12-12 Pfizer Prod Inc Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer

Also Published As

Publication number Publication date
CA2542279C (en) 2011-08-09
IL174299A (en) 2011-12-29
IL174299A0 (en) 2006-08-01
NO337361B1 (no) 2016-03-29
JP2007508374A (ja) 2007-04-05
UA86037C2 (ru) 2009-03-25
BRPI0415356A (pt) 2006-12-12
EP1680124B1 (en) 2017-05-31
EP1680124A4 (en) 2009-05-13
GEP20104959B (en) 2010-04-26
CA2542279A1 (en) 2005-04-28
JP4732354B2 (ja) 2011-07-27
KR20060095865A (ko) 2006-09-04
CN1867338A (zh) 2006-11-22
AP2006003592A0 (en) 2006-04-30
ECSP066504A (es) 2006-10-10
TNSN06109A1 (fr) 2007-11-15
WO2005037216A2 (en) 2005-04-28
WO2005037216A3 (en) 2005-08-04
IS8355A (is) 2006-03-16
AU2004281794B2 (en) 2010-04-22
US7473787B2 (en) 2009-01-06
JP2011157358A (ja) 2011-08-18
ZA200602174B (en) 2007-04-25
EA200600513A1 (ru) 2006-08-25
US20050096375A1 (en) 2005-05-05
RS20060190A (sr) 2008-08-07
CR20110095A (es) 2011-03-09
MA28094A1 (fr) 2006-08-01
EP1680124A2 (en) 2006-07-19
DK1680124T3 (en) 2017-08-21
CN101838271A (zh) 2010-09-22
AU2004281794A1 (en) 2005-04-28
EA009903B1 (ru) 2008-04-28
MXPA06004279A (es) 2006-06-28
CR8333A (es) 2007-08-14
NZ546012A (en) 2009-12-24
ES2634841T3 (es) 2017-09-29

Similar Documents

Publication Publication Date Title
NO20062193L (no) Bisykliske [3.1.0] derivater som glysintransportorinhibitorer
NO20074993L (no) Bisykliske [3 0 1]heteroaryl amider som type 1 glysin transport inhibitorer
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
GEP20074055B (en) Nicotinamide derivatives useful as pde4 inhibitors
CY1109765T1 (el) Αζα- δικυκλοαλκυλο αιθερες και η χρηση τους ως αγωνιστες aλφα7-nachr
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
UY27368A1 (es) Nuevos compuestos
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
MY135841A (en) Novel benzodioxoles
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
DE602005023015D1 (de) Indolderivate als viruzide
ATE428422T1 (de) Piperidin-derivate als ccr3-antagonisten
DE69522945D1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
SE9701304D0 (sv) Compounds
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
ATE186301T1 (de) An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PFIZER PRODUCTS INC, US

MM1K Lapsed by not paying the annual fees